Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion ...

5 September 2026 · By · Wire by Fusion42

Published

5 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at ncnewsonline.com →

◆ Verified

Fusion42 · 5 September 2026 · Fusion42 review

The FDA approved Guardant360 CDx as the first liquid biopsy companion diagnostic for identifying ESR1 mutations in advanced HR-positive breast cancer to enable early therapeutic intervention with AstraZeneca's ETCAMAH before radiographic progression.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You can now build services around earlier breast cancer intervention using liquid biopsy, as Guardant360 opens access to adaptive cancer treatment before visible progression. This FDA nod forces therapy players to integrate ctDNA testing to stay relevant in breast cancer care.

◆ Coverage

1 source · 5 Sep 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalliquid-biopsybreast-cancerprecision-medicinecompanion-diagnostic